相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody
Nobuhiko Kanaya et al.
MOLECULAR THERAPY (2020)
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors
Caroline E. Porter et al.
MOLECULAR THERAPY (2020)
NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer
Elaine Y. L. Leung et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade
Chaolong Lin et al.
CANCER IMMUNOLOGY RESEARCH (2020)
TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling
Camilla Heinio et al.
CELLS (2020)
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
Jean-Pascal Machiels et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-B pathway
Lu Jiang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Optimizing oncolytic virotherapy in cancer treatment
Kevin Harrington et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC
Yonghui Zhang et al.
MOLECULAR THERAPY (2019)
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
Hauke Stamm et al.
ONCOIMMUNOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
Lukasz Kuryk et al.
ONCOIMMUNOLOGY (2019)
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Dmitriy Zamarin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model
Lukasz Kuryk et al.
JOURNAL OF MEDICAL VIROLOGY (2018)
Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
Stacy J. Kowalsky et al.
MOLECULAR THERAPY (2018)
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
Jacob M. Ricca et al.
MOLECULAR THERAPY (2018)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
Hauke Stamm et al.
ONCOGENE (2018)
Oncolytic viruses as engineering platforms for combination immunotherapy
Kwame Twumasi-Boateng et al.
NATURE REVIEWS CANCER (2018)
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
M. H. Pollack et al.
ANNALS OF ONCOLOGY (2018)
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
Nicholas A. Manieri et al.
TRENDS IN IMMUNOLOGY (2017)
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
Zuqiang Liu et al.
NATURE COMMUNICATIONS (2017)
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
Rocio Garcia-Carbonero et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
Mee Y. Bartee et al.
CANCER RESEARCH (2017)
The untold story of IFN-γ in cancer biology
M. Alper Kursunel et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2016)
Oncolytic viruses-immunotherapeutics on the rise
Brian A. Keller et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression
Emeline Ragonnaud et al.
VACCINE (2016)
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
Juan J. Rojas et al.
CLINICAL CANCER RESEARCH (2015)
Arming oncolytic viruses to leverage antitumor immunity
Tanja D. de Gruijl et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific
Tina M. Cairns et al.
JOURNAL OF VIROLOGY (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Potentiation of anti-glioma immunity induced by oncolytic adenovirus Delta-24-RGD through viral expression of immune co-stimulator OX40 ligand
Hong Jiang et al.
Journal for ImmunoTherapy of Cancer (2015)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit
Kristen E. Pauken et al.
CANCER CELL (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity
Zong Sheng Guo et al.
FRONTIERS IN ONCOLOGY (2014)
Going viral with cancer immunotherapy
Brian D. Lichty et al.
NATURE REVIEWS CANCER (2014)
Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell Response
Seung-Pil Shin et al.
MOLECULAR THERAPY (2013)
Oncolytic Virus and Anti-4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer
Liza B. John et al.
CANCER RESEARCH (2012)
Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1BB Ligand
Hong Sung Kim et al.
CANCER RESEARCH (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma
DP Xu et al.
GENE THERAPY (2005)
Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule
C Bottino et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
分享论文
